Sarcomas | Specialty

Regulatory Approval Sought for Eribulin in Soft Tissue Sarcoma

July 30th 2015

An application has been submitted to the FDA for eribulin mesylate (Halaven) as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

Dr. George Demetri on Trabectedin for Sarcomas

July 24th 2015

George D. Demetri, MD, Director, Center for Sarcoma and Bone Oncology Senior Vice President for Experimental Therapeutics, Professor of Medicine, Harvard Medical School, Dana Farber Cancer Center, discusses a phase III study of trabectedin verus dacarbazine for the treatment of patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Regulatory Review of Trabectedin for Advanced STS

July 2nd 2015

Chemotherapy for Advanced Sarcoma

July 2nd 2015

Treating Refractory or Recurrent Soft Tissue Sarcoma

July 2nd 2015

Factors Impacting the Classification and Diagnosis of STS

July 2nd 2015

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

June 5th 2015

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Dr. Van Tine on Trabectedin for Leiomyosarcoma and Liposarcoma

June 3rd 2015

Brian A. Van Tine, MD, PhD, Assistant Professor Department of Medicine Siteman Cancer Center, Washington University School of Medicine, discusses trabectedin (Yondelis) for the treatment of soft tissue sarcomas.

Trabectedin Extends PFS in Phase III Soft Tissue Sarcoma Study

June 3rd 2015

Trabectedin reduced the risk of disease progression by 45% versus dacarbazine in patients with advanced soft tissue sarcoma.

Eribulin Elicits Survival Advantage in Phase III Sarcoma Study

May 31st 2015

Treatment with eribulin (Halaven) improved overall survival by 2 months compared with dacarbazine in patients with advanced leiomyosarcoma and adipocytic sarcoma.

Eribulin Extends Survival in Phase III Sarcoma Study

February 25th 2015

Treatment with eribulin mesylate significantly extended overall survival compared with dacarbazine in patients with advanced soft tissue sarcoma.

Lung Cancer Screening, Trabectedin in Soft Tissue Sarcoma, and More

February 12th 2015

Palbociclib: An Exciting New Option in Breast Cancer

February 12th 2015

Integrating Palbociclib Into the Treatment of Breast Cancer

February 12th 2015

Preclinical and Clinical Evidence Supporting Palbociclib

February 12th 2015

Trabectedin Receives Priority Review for Advanced Soft Tissue Sarcoma

February 3rd 2015

The FDA has granted a priority review to trabectedin (Yondelis) to treat patients with advanced soft tissue sarcoma.

Dr. Van Tine Discusses Potential Novel Treatment Modalities for Sarcoma

July 23rd 2014

Brian A. Van Tine, MD, PhD, assistant professor, Washington University School of Medicine in St. Louis, discusses some potential novel treatment modalities for the treatment of sarcoma.

Dr. Movva on Molecular Profiling in Sarcoma

July 16th 2014

Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses a study presented at the 2014 ASCO Annual Meeting where researchers profiled more than 1900 sarcoma specimens to try to identify potential novel treatment modalities for patients with this disease.

Patient's Twenty-Pound Tumor Sheds Light on Liposarcoma - A Rare Form of Soft Tissue Cancer

July 14th 2014

Surgical Team at NYU Langone Medical Center Successfully Removes Life-Threatening Retroperitoneal Mass Along with Several Organs -- Staten Island Resident Expresses His Thanks

Dr. Tap on Combined KIT and CTLA-4 Blockade in Patients with GIST

July 10th 2014

William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the idea of using combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.